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52-3042/Copyright ª 2014, ChongqBacteria and archaea have been known for decades having
evolvedadaptive immunedefenses calledclustered regularly
interspaced short palindromic repeats (CRISPR)/CRISPR-
associated (Cas) systems to degrade foreign nucleic acids.
Recently, these RNA-guided Cas9 nucleases derived from
CRISPR/Cas systems have shown promise in transforming our
ability to edit mammalian genomes.1 While zinc-finger nu-
cleases (ZFNs) and transcription activator-like effector nu-
cleases (TALENs) have shown similar promise, the ease of
producing targeting RNAs over the generation of unique
sequence-directed nucleases to guide site-specific modifi-
cations makes the CRISPR/Cas9 system an appealing method
for genomeediting.A short guideRNA (sgRNA)candirectCas9
to a specific genomic sequence where it induces double-
strand breaks that, when imperfectly repaired, yield muta-
tions.1 Cas9 can also catalyze gene replacement through
homologous recombination.1 Undoubtedly, Cas9-mediated
genome editing and regulation should have transformative
potential for basic science, genome engineering and
therapeutics.1
However, the specificity of CRISPR/Cas9 targeting
technology remains problematic. It’s been noted that
sgRNA-Cas9 complexes are in general tolerant of 1w3,
occasionally more, mismatches in their targets, as Cas9 wasity of Chongqing Medical
014.08.004
ing Medical University. Productionshown to bind to many sites in human genome other than
the desired one.2 Thus, imperfect Cas9 specificity is a
major concern, while several attempts have been made to
improve CRISPR specificity, such as using multiple sgRNA-
Cas9 complexes for activity, discovering improved natural
Cas orthologs, engineering improved Cas9 variants and
judiciously choosing targeting sgRNAs.3
Two recent studies reported an innovative approach to
addressing the problem of off-target genomic cleavage
using CRISPR-Cas9 system.4,5 Both studies took advantage
of the known feature of dimerization dependence for Cas9-
mediated cleavage and the proven specificity of ZFNs and
TALENs. To achieve this feat, the investigators engineered
dimeric nucleases by fusing dCas9 with the Fok1 nuclease,
which is the obligatory dimeric nuclease used in ZFNs and
TALENs.4,5 The resulting Cas9-Fok1 fusion constructs
contain that Fok1 nuclease is fused to the N-terminus of
inactive Cas9 in the opposite orientation to that in ZFN and
TALENs. The researchers showed that in the optimal
configuration the on-target cleavage efficiency of these
dimeric Cas9-Fok1 fusions is slightly lower than or compa-
rable to that of wild-type Cas9.4,5 The requirement for two
gRNAs for precise orientation of the target sites and for
correct spacing between half-sites is more stringent for the
Cas9-Fok1 fusion construct than that for Cas9 nickase,
which is a Cas9 variant that cleaves one DNA strand only.
Deep sequencing analysis of the previously identified off-
target sites of wild-type Cas9 revealed the dimeric Fok1-
dCas9 fusion construct has significantly lower off-target
activity than that of wild-type Cas9 nuclease.4,5 One
major caveat of this approach is that the more stringent
sequence requirements of the dimeric Fok1-dCas9 nucle-
ases will likely reduce the number of available on-target
sites. Nonetheless, the requirement of binding to two
precisely disposed genomic targetable half-sites should
render Cas9-Fok1 fusion nucleases substantially improved
on-target specificity. In a broader sense, the development
of dimeric Fok1-dCas9 fusions may prove a significant
turning point towards practical mammalian genome ma-
nipulations with high efficiency and accuracy.and hosting by Elsevier B.V. All rights reserved.
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